Literature DB >> 9300353

Characterization of four basic models of indirect pharmacodynamic responses.

A Sharma1, W J Jusko.   

Abstract

Four basic models of indirect pharmacodynamic responses were characterized in terms of changing dose, Imax or Smax, and IC50 or SC50 to examine the effects of these fundamental drug properties on response profiles. Standard pharmacokinetic parameters were used for generating plasma concentration, and response-time profiles using computer simulations. Comparisons to theoretical expectations were made. In all four models, the maximum response (Rmax) (inhibition or stimulation) and the time of its occurrence (TRmax) were dependent on the model, dose, Imax or Smax, and IC50 or SC50 values. An increase in dose or a decrease in IC50 or SC50 by the same factor produced, as theoretically expected, identical and superimposable pharmacodynamic response patterns in each of the models. Some parameters (TRmax, ABEC) were nearly proportional to log dose, while others (Rmax, CRmax) were nonlinear. Assessment of expected response signature patterns as demonstrated in this report may be helpful in experimental designs and in assigning appropriate models to pharmacodynamic data.

Entities:  

Mesh:

Year:  1996        PMID: 9300353     DOI: 10.1007/BF02353483

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  13 in total

1.  Integrated functions for four basic models of indirect pharmacodynamic response.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharm Sci       Date:  1998-01       Impact factor: 3.534

2.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

3.  Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin.

Authors:  R Nagashima; R A O'Reilly; G Levy
Journal:  Clin Pharmacol Ther       Date:  1969 Jan-Feb       Impact factor: 6.875

4.  Pharmacodynamic modeling of prednisolone effects on natural killer cell trafficking.

Authors:  Z X Xu; M J Lee; R A Blum; W J Jusko
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

5.  Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking.

Authors:  M A Milad; E A Ludwig; S Anné; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

6.  Convergence of direct and indirect pharmacodynamic response models.

Authors:  W J Jusko; H C Ko; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

7.  Comparison of four basic models of indirect pharmacodynamic responses.

Authors:  N L Dayneka; V Garg; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

8.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects.

Authors:  W J Jusko; H C Ko
Journal:  Clin Pharmacol Ther       Date:  1994-10       Impact factor: 6.875

9.  Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics.

Authors:  J A Wald; D E Salazar; H Y Chen; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

10.  Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.

Authors:  K H Lew; E A Ludwig; M A Milad; K Donovan; E Middleton; J J Ferry; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1993-10       Impact factor: 6.875

View more
  46 in total

1.  Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

2.  Characterization of pharmacodynamic recession slopes for direct and indirect response models.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1998-08

3.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

4.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.

Authors:  A Dupuis; W Couet; J Paquereau; S Debarre; A Portron; C Jamois; S Bouquet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

6.  A method of obtaining starting values of k(in) and k(out) for the indirect response models.

Authors:  Debu Mukherjee; Matthew M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

Review 7.  Prediction of exposure-response relationships to support first-in-human study design.

Authors:  John P Gibbs
Journal:  AAPS J       Date:  2010-10-22       Impact factor: 4.009

8.  Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.

Authors:  Dhananjay D Marathe; Anshu Marathe; Donald E Mager
Journal:  Biopharm Drug Dispos       Date:  2011-09-22       Impact factor: 1.627

9.  A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

Authors:  Chuanpu Hu; Zhenling Yao; Yang Chen; Bruce Randazzo; Liping Zhang; Zhenhua Xu; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-16       Impact factor: 2.745

Review 10.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.